










[Back to Search Results](#)

Genomic Basis of Susceptibility to COVID-19 Infection and its Complications

- Description
-  [Details](#)
-  [Sub-Projects](#)
-  [Publications](#)
-  [Patents](#)
-  [Outcomes](#)
-  [Clinical Studies](#)
-  [News and More](#)
-  [History](#)
-  [Similar Projects](#)

Project Number	Former Number	Contact	Awardee
3U01HG006379-09S1	3U01HG006379-08S1	PI/Project Leader KULLO, IFTIKHAR JOther PIs	Organization MAYO CLINIC ROCHESTER

Description

Abstract Text

PROJECT SUMMARY In addition to causing millions of cases and hundreds of thousands of deaths, the Coronavirus disease 2019 (**COVID-19**) pandemic has brought life and economic activity to a near standstill in many parts of the world. A coordinated scientific effort is necessary to mitigate the widespread misery, morbidity and mortality inflicted by the pandemic. The goal of this supplemental application is to contribute to informatics and genomics efforts to identify the genomic basis of susceptibility to and complications of **COVID-19**. The wide spectrum of disease severity with **COVID-19** is only partially explained by age and medical comorbidities and genetic factors are likely to play a key role. Identifying genomic factors impacting **COVID-19** case status and complications is important for risk stratification, identifying new pathophysiologic pathways for drug development/repurposing, and improved understanding of the biology of SARS-CoV-2 infection and its complications. As part of the electronic Medical Records and Genomics (eMERGE) since its inception in 2007, Mayo investigators have considerable experience in using the electronic health record (EHR) for genomics research. We will develop electronic phenotyping algorithms to ascertain **COVID-19** case status, complications and fatality, to identify genomic variants associated with adverse outcomes. Using DNA samples linked to the EHR, we will perform genomic analyses to identify common and rare variants associated with case status, case severity and case mortality. We will collaborate with health systems and consortia in the US and around the world to increase the power and rapidity of the genomic studies. Our specific aims are: Specific Aim 1: Develop and validate electronic phenotyping algorithms to ascertain **COVID-19** related phenotypes including case control status, i.e., individuals tested and those were identified to be positive for **COVID-19**, and disease severity, in particular cardiovascular complications including myocardial injury/infarction, arrhythmias, coagulopathy as well as large vessel thrombosis. Specific Aim 2: Perform genomic association analyses to identify variants associated with susceptibility to infection with SARS-CoV-2 and its complications. We will compare test +ve vs test -ve individuals, mild vs hospitalized cases of **COVID-19** and among the latter those who develop severe disease or die. In addition to genome-wide association studies (GWAS), we will conduct association studies of the HLA region and burden tests using sequence data.


Public Health Relevance Statement

PROJECT NARRATIVE A coordinated scientific effort is necessary to mitigate the widespread misery, morbidity and mortality inflicted by the COVID-19 pandemic. The goal of this supplemental application is to identify the genetic factors that predispose individuals develop severe complications after COVID-19 infection. Identifying such factors is important for risk stratification, finding new pathways for drug development/repurposing, and to improve our understanding of the biology of SARS-CoV-2 infection and its complications.

NIH Spending Category

Biotechnology Cardiovascular Clinical Research Coronaviruses
Emerging Infectious Diseases Genetics Hematology Human Genome
Infectious Diseases

Project Terms

 Thank you for your feedback!

[Back to Search Results](#)

Genomic Basis of Susceptibility to COVID-19 Infection and its Complications

- Description
- [Details](#)
- [Sub-Projects](#)
- [Publications](#)
- [Patents](#)
- [Outcomes](#)
- [Clinical Studies](#)
- [News and More](#)
- [History](#)
- [Similar Projects](#)

Project Number 3U01HG006379-09S1	Former Number 3U01HG006379-08S1	Contact PI/Project Leader KULLO, IFTIKHAR JOther PIs	Awardee Organization MAYO CLINIC ROCHESTER
Electronic Medical Records and Genomics Network		Genes	Genetic
Genomic approach	Genomics	Goals	HLA Antigens
Individual	Infarction	Infection	Inflammasome
			Informatics
			Life
			Link
Read More			

Details

Contact PI/ Project Leader

Name
[KULLO, IFTIKHAR J](#)

Title
PROFESSOR

Contact
KULLO.IFTIKHAR@MAYO.EDU

Other PIs

Name
[SHARP, RICHARD R.](#)

Program Official

Name
ROWLEY, ROBB KENNETH

Contact
robb.rowley@nih.gov

Organization

Name MAYO CLINIC ROCHESTER	Department Type Unavailable	State Code MN
City ROCHESTER	Organization Type Other Domestic Non-Profits	Congressional District 01
Country UNITED STATES (US)		

Other Information

FOA PA-18-591	Administering Institutes or Centers NATIONAL HUMAN GENOME RESEARCH INSTITUTE	Project Start Date 15-August-2011
Study Section ZHG1(J2)	DUNS Number CFDA Code 006471700 172	Project End Date 30-April-2025
Fiscal Year 2020	Award Notice Date 16-September-2020	Budget Start Date 16-September-2020
		Budget End Date 30-April-2021

Project Funding Information for 2020

Total Funding \$282,848	Direct Costs \$177,892	Indirect Costs \$104,956
-----------------------------------	----------------------------------	------------------------------------

Year	Funding IC	FY Total
2020	NATIONAL HUMAN GENOME RESEARCH INSTITUTE	\$282,848

NIH Categorical Spending










[Click here for more information on NIH Categorical Spending](#)

Funding IC	FY Total Cost by IC	NIH Spending Category

Thank you for your feedback!

[Back to Search Results](#)

Genomic Basis of Susceptibility to COVID-19 Infection and its Complications

- Description
-  [Details](#)
 -  [Sub-Projects](#)
 -  [Publications](#)
 -  [Patents](#)
 -  [Outcomes](#)
 -  [Clinical Studies](#)
 -  [News and More](#)
 -  [History](#)
 -  [Similar Projects](#)

Project Number
3U01HG006379-
09S1

Former Number
3U01HG006379-
08S1

Contact
PI/Project Leader
KULLO, IFTIKHAR
[JOther PIs](#)

Awardee
Organization
MAYO CLINIC
ROCHESTER

Genome; Infectious
Diseases;

Sub Projects

No Sub Projects information available for 3U01HG006379-09S1

Publications

No Publications available for 3U01HG006379-09S1

Patents

No Patents information available for 3U01HG006379-09S1

Outcomes

The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.

No Outcomes available for 3U01HG006379-09S1

Clinical Studies

No Clinical Studies information available for 3U01HG006379-09S1

News and More

Related News Releases

No news release information available for 3U01HG006379-09S1

History

No Historical information available for 3U01HG006379-09S1

Thank you for your feedback!

[Back to Search Results](#)

Genomic Basis of Susceptibility to COVID-19 Infection and its Complications

Description	Project Number	Former Number	Contact	Awardee
 Details	3U01HG006379-09S1	3U01HG006379-08S1	PI/Project Leader KULLO, IFTIKHAR JOther PIs	Organization MAYO CLINIC ROCHESTER
 Sub-Projects				
 Publications				
 Patents				
 Outcomes				
 Clinical Studies				
 News and More				
 History				
 Similar Projects				

Thank you for your feedback!